person · Reporting owner

LEE ANN L.

Disclosed activity across 2 companies

Tapewire entity: 64974
SEC CIK: 0001723629

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Prime Medicine, Inc.PRME · Entity 5281	Chief Technical Officer	February 23, 2026	February 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Prime Medicine, Inc.

Report date February 23, 2026 · Filed February 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2036-02-23	Direct	375,000	Reported balance After 2026-02-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-23 · Grant · Acquired 375,000 · Balance 375,000 F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Juno Therapeutics, Inc.

Report date March 05, 2018 · Filed March 07, 2018

Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-03-05 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2018-03-05 · Disposition to issuer · Disposed 35,004 · Balance 75,788 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Represents time-based restricted stock awards ("RSAs"). F3: Pursuant to the Merger Agreement, the vested portion of such RSAs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSAs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSAs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Row 2 · 2018-03-05 · Disposition to issuer · Disposed 40,788 · Balance 35,000 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F5: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Row 3 · 2018-03-05 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: Represents performance-based restricted stock awards ("PSAs"). F7: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.85 · Expires 2027-11-24	Direct	0	Reported balance After 2018-03-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-03-05 · Disposition to issuer · Disposed 152,900 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F8: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).

Filing footnotes · ownership attribution and instrument terms

F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.

F2: Represents time-based restricted stock awards ("RSAs").

F3: Pursuant to the Merger Agreement, the vested portion of such RSAs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSAs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSAs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement).

F4: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs").

F5: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement).

F6: Represents performance-based restricted stock awards ("PSAs").

F7: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017.

F8: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 23, 2026 Filed Feb 24, 2026 22:07 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	375,000	$0.00 Strike: $3.34	$0.00	Disclosure SEC source: 0001628280-26-011208 · wk-form4_1771970849.xml · derivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2036-02-23 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
August 01, 2025 Filed Aug 6, 2025 00:44 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	180,995	Not disclosed Strike: $4.04	Not disclosed	Disclosure SEC source: 0001894562-25-000051 · wk-form4_1754441078.xml · derivative · entry 4 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,995 Underlying: Common Stock · 180,995 shares Expires 2034-02-21 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
August 01, 2025 Filed Aug 6, 2025 00:44 UTC	Prime Medicine, Inc. PRME · Entity 5281	Disposition to issuerStock Option (right to buy) · Derivative	180,995	Not disclosed Strike: $8.49	Not disclosed	Disclosure SEC source: 0001894562-25-000051 · wk-form4_1754441078.xml · derivative · entry 3 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 180,995 shares Expires 2034-02-21 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
August 01, 2025 Filed Aug 6, 2025 00:44 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	180,995	Not disclosed Strike: $4.04	Not disclosed	Disclosure SEC source: 0001894562-25-000051 · wk-form4_1754441078.xml · derivative · entry 2 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,995 Underlying: Common Stock · 180,995 shares Expires 2033-03-31 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
August 01, 2025 Filed Aug 6, 2025 00:44 UTC	Prime Medicine, Inc. PRME · Entity 5281	Disposition to issuerStock Option (right to buy) · Derivative	180,995	Not disclosed Strike: $12.30	Not disclosed	Disclosure SEC source: 0001894562-25-000051 · wk-form4_1754441078.xml · derivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 180,995 shares Expires 2033-03-31 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
May 21, 2025 Filed May 22, 2025 20:21 UTC	Prime Medicine, Inc. PRME · Entity 5281	PurchaseCommon Stock	100,000	$1.13	$113,000.00	Disclosure SEC source: 0001894562-25-000028 · wk-form4_1747945273.xml · nonDerivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Read SEC document
May 08, 2025 Filed May 12, 2025 20:48 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	80,416	$0.00 Strike: $3.67	$0.00	Disclosure SEC source: 0001894562-25-000018 · wk-form4_1747082905.xml · derivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,248 Underlying: Common Stock · 80,416 shares Expires 2031-10-27 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on October 27, 2021, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 80,416 shares. Read SEC document
February 27, 2025 Filed Mar 4, 2025 01:14 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	275,000	$0.00 Strike: $2.42	$0.00	Disclosure SEC source: 0001894562-25-000006 · wk-form4_1741050835.xml · derivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
May 17, 2024 Filed May 21, 2024 20:10 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	80,416	$0.00 Strike: $3.67	$0.00	Disclosure SEC source: 0001894562-24-000022 · wk-form4_1716322214.xml · derivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,832 Underlying: Common Stock · 80,416 shares Expires 2031-10-27 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on October 27, 2021, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 17, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 80,416 shares. Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:02 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	180,995	$0.00 Strike: $8.49	$0.00	Disclosure SEC source: 0001894562-24-000012 · wk-form4_1708725737.xml · derivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,995 Underlying: Common Stock · 180,995 shares Expires 2034-02-21 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 21, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:22 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	180,995	$0.00 Strike: $12.30	$0.00	Disclosure SEC source: 0001894562-23-000002 · wf-form4_168065413914963.xml · derivative · entry 1 LEE ANN L. · CIK 0001723629 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,995 Underlying: Common Stock · 180,995 shares Expires 2033-03-31 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:22 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	152,900	Not disclosed Strike: $62.85	Not disclosed	Disclosure SEC source: 0001209191-18-017820 · doc4.xml · derivative · entry 4 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,900 shares Expires 2027-11-24 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F8 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F8 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:22 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	35,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-017820 · doc4.xml · nonDerivative · entry 3 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · shares: Represents performance-based restricted stock awards ("PSAs"). F7 · price: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017. Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:22 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	40,788	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-017820 · doc4.xml · nonDerivative · entry 2 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · shares: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F5 · price: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:22 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	35,004	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-017820 · doc4.xml · nonDerivative · entry 1 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,788 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Represents time-based restricted stock awards ("RSAs"). F3 · price: Pursuant to the Merger Agreement, the vested portion of such RSAs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSAs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSAs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
January 31, 2018 Filed Feb 2, 2018 19:33 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GrantCommon Stock	40,788	$0.00	$0.00	Disclosure SEC source: 0001209191-18-007218 · doc4.xml · nonDerivative · entry 1 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,792 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018. Read SEC document
November 25, 2017 Filed Nov 28, 2017 19:26 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GrantStock Opton (Right to Buy) · Derivative	152,900	$0.00 Strike: $62.85	$0.00	Disclosure SEC source: 0001209191-17-062760 · doc4.xml · derivative · entry 3 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,900 Underlying: Common Stock · 152,900 shares Expires 2027-11-24 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on November 25, 2018 and 1/48th of the shares subject to the option shall vest and become exercisable monthly thereafter. Read SEC document
November 25, 2017 Filed Nov 28, 2017 19:26 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GrantCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-062760 · doc4.xml · nonDerivative · entry 2 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,004 F2 · shares: Represents a RSA granted pursuant to the 2014 Equity Incentive Plan. The RSA will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date: Up to 21,000 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the "FDA") of JCAR017 in any indication within certain designated timeframes (the "JCAR017 Milestone"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement. Up to 9,000 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes. Read SEC document
November 25, 2017 Filed Nov 28, 2017 19:26 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GrantCommon Stock	35,004	$0.00	$0.00	Disclosure SEC source: 0001209191-17-062760 · doc4.xml · nonDerivative · entry 1 LEE ANN L. · CIK 0001723629 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,004 F1 · shares: Represents a restricted stock award ("RSA") granted pursuant to the 2014 Equity Incentive Plan. 50% of the shares subject to the RSA shall vest on each anniversary of November 25, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.